|
Code
|
Display
|
|
24
|
anthrax vaccine |
|
181
|
anthrax immune globulin |
|
19
|
Bacillus Calmette-Guerin vaccine |
|
27
|
botulinum antitoxin |
|
173
|
cholera, BivWC |
|
174
|
cholera, live attenuated |
|
26
|
cholera vaccine, unspecified formulation |
|
172
|
cholera, WC-rBS |
|
510
|
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) |
|
511
|
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) |
|
502
|
SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) |
|
211
|
SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose |
|
212
|
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL |
|
210
|
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL |
|
218
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation |
|
207
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose |
|
219
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation |
|
208
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose |
|
217
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation |
|
221
|
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose |
|
56
|
dengue fever vaccine |
|
12
|
diphtheria antitoxin |
|
28
|
diphtheria and tetanus toxoids, adsorbed for pediatric use |
|
195
|
Diphtheria, Tetanus, Poliomyelitis adsorbed |
|
20
|
diphtheria, tetanus toxoids and acellular pertussis vaccine |
|
106
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens |
|
107
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, unspecified formulation |
|
146
|
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine |
|
170
|
non-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
|
110
|
DTaP-hepatitis B and poliovirus vaccine |
|
50
|
DTaP-Haemophilus influenzae type b conjugate vaccine |
|
120
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
|
130
|
Diphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivated |
|
132
|
Historical diphtheria and tetanus toxoids and acellular pertussis, poliovirus, Haemophilus b conjugate and hepatitis B (recombinant) vaccine. |
|
01
|
diphtheria, tetanus toxoids and pertussis vaccine |
|
198
|
Diphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent) |
|
22
|
DTP-Haemophilus influenzae type b conjugate vaccine |
|
102
|
DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine |
|
30
|
hepatitis B immune globulin |
|
52
|
hepatitis A vaccine, adult dosage |
|
169
|
Hep A, live attenuated-IM |
|
83
|
hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule |
|
84
|
hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule |
|
85
|
hepatitis A vaccine, unspecified formulation |
|
104
|
hepatitis A and hepatitis B vaccine |
|
193
|
hepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US) |
|
08
|
hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
|
42
|
hepatitis B vaccine, adolescent/high risk infant dosage |
|
43
|
hepatitis B vaccine, adult dosage |
|
44
|
hepatitis B vaccine, dialysis patient dosage |
|
45
|
hepatitis B vaccine, unspecified formulation |
|
189
|
Hepatitis B vaccine (recombinant), CpG adjuvanted |
|
47
|
Haemophilus influenzae type b vaccine, HbOC conjugate |
|
46
|
Haemophilus influenzae type b vaccine, PRP-D conjugate |
|
49
|
Haemophilus influenzae type b vaccine, PRP-OMP conjugate |
|
48
|
Haemophilus influenzae type b vaccine, PRP-T conjugate |
|
17
|
Haemophilus influenzae type b vaccine, conjugate unspecified formulation |
|
51
|
Haemophilus influenzae type b conjugate and Hepatitis B vaccine |
|
118
|
human papilloma virus vaccine, bivalent |
|
62
|
human papilloma virus vaccine, quadrivalent |
|
86
|
immune globulin, intramuscular |
|
14
|
immune globulin, unspecified formulation |
|
87
|
immune globulin, intravenous |
|
160
|
Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 |
|
151
|
influenza nasal, unspecified formulation |
|
123
|
influenza virus vaccine, H5N1, A/Vietnam/1203/2004 (national stockpile) |
|
135
|
influenza, high dose seasonal, preservative-free |
|
197
|
influenza, high-dose seasonal, quadrivalent, preservative free |
|
153
|
Influenza, injectable, Madin Darby Canine Kidney, preservative free |
|
171
|
Influenza, injectable, Madin Darby Canine Kidney, preservative free, quadrivalent |
|
186
|
Influenza, injectable, Madin Darby Canine Kidney, quadrivalent with preservative |
|
158
|
influenza, injectable, quadrivalent, contains preservative |
|
150
|
Influenza, injectable, quadrivalent, preservative free |
|
161
|
Influenza, injectable,quadrivalent, preservative free, pediatric |
|
166
|
influenza, intradermal, quadrivalent, preservative free, injectable |
|
111
|
influenza virus vaccine, live, attenuated, for intranasal use |
|
149
|
influenza, live, intranasal, quadrivalent |
|
155
|
Seasonal, trivalent, recombinant, injectable influenza vaccine, preservative free |
|
185
|
Seasonal, quadrivalent, recombinant, injectable influenza vaccine, preservative free |
|
141
|
Influenza, seasonal, injectable |
|
140
|
Influenza, seasonal, injectable, preservative free |
|
144
|
seasonal influenza, intradermal, preservative free |
|
194
|
Influenza, Southern Hemisphere, unspecified formulation (Non-US) |
|
200
|
influenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative free |
|
201
|
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, no preservative |
|
202
|
influenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservative |
|
15
|
influenza virus vaccine, split virus (incl. purified surface antigen)-retired CODE |
|
168
|
Seasonal trivalent influenza vaccine, adjuvanted, preservative free |
|
88
|
influenza virus vaccine, unspecified formulation |
|
16
|
influenza virus vaccine, whole virus |
|
10
|
poliovirus vaccine, inactivated |
|
134
|
Japanese Encephalitis vaccine for intramuscular administration |
|
39
|
Japanese Encephalitis Vaccine SC |
|
129
|
Japanese Encephalitis vaccine, unspecified formulation |
|
66
|
Lyme disease vaccine |
|
04
|
measles and rubella virus vaccine |
|
05
|
measles virus vaccine |
|
191
|
meningococcal A polysaccharide vaccine (non-US) |
|
192
|
meningococcal AC polysaccharide vaccine (non-US) |
|
108
|
meningococcal ACWY vaccine, unspecified formulation |
|
163
|
meningococcal B vaccine, recombinant, OMV, adjuvanted |
|
162
|
meningococcal B vaccine, fully recombinant |
|
164
|
meningococcal B, unspecified formulation |
|
103
|
meningococcal C conjugate vaccine |
|
148
|
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine |
|
147
|
Meningococcal, MCV4, unspecified conjugate formulation(groups A, C, Y and W-135) |
|
136
|
meningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O) |
|
114
|
meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P) |
|
32
|
meningococcal polysaccharide vaccine (MPSV4) |
|
167
|
meningococcal vaccine of unknown formulation and unknown serogroups |
|
03
|
measles, mumps and rubella virus vaccine |
|
94
|
measles, mumps, rubella, and varicella virus vaccine |
|
07
|
mumps virus vaccine |
|
998
|
no vaccine administered |
|
127
|
Novel influenza-H1N1-09, injectable |
|
128
|
Novel influenza-H1N1-09, all formulations |
|
125
|
Novel Influenza-H1N1-09, live virus for nasal administration |
|
126
|
Novel influenza-H1N1-09, preservative-free, injectable |
|
02
|
trivalent poliovirus vaccine, live, oral |
|
179
|
Non-US monovalent oral polio vaccine, unspecified formulation |
|
178
|
Non-US bivalent oral polio vaccine (types 1 and 3) |
|
182
|
Oral Polio Vaccine, Unspecified formulation |
|
69
|
parainfluenza-3 virus vaccine |
|
177
|
pneumococcal conjugate vaccine, 10 valent |
|
11
|
pertussis vaccine |
|
23
|
plague vaccine |
|
133
|
pneumococcal conjugate vaccine, 13 valent |
|
100
|
pneumococcal conjugate vaccine, 7 valent |
|
152
|
Pneumococcal Conjugate, unspecified formulation |
|
33
|
pneumococcal polysaccharide vaccine, 23 valent |
|
109
|
pneumococcal vaccine, unspecified formulation |
|
89
|
poliovirus vaccine, unspecified formulation |
|
175
|
Human Rabies vaccine from human diploid cell culture |
|
176
|
Human rabies vaccine from Chicken fibroblast culture |
|
40
|
rabies vaccine, for intradermal injection |
|
90
|
rabies vaccine, unspecified formulation |
|
159
|
Rho(D) Unspecified formulation |
|
157
|
Rho(D) Immune globulin - IM |
|
156
|
Rho(D) Immune globulin- IV or IM |
|
34
|
rabies immune globulin |
|
71
|
respiratory syncytial virus immune globulin, intravenous |
|
93
|
respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular |
|
06
|
rubella virus vaccine |
|
38
|
rubella and mumps virus vaccine |
|
213
|
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED |
|
76
|
Staphylococcus bacteriophage lysate |
|
138
|
tetanus and diphtheria toxoids, not adsorbed, for adult use |
|
09
|
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
|
113
|
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid) |
|
139
|
Td(adult) unspecified formulation |
|
196
|
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified |
|
115
|
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed |
|
180
|
tetanus immune globulin |
|
35
|
tetanus toxoid, adsorbed |
|
142
|
tetanus toxoid, not adsorbed |
|
112
|
tetanus toxoid, unspecified formulation |
|
77
|
tick-borne encephalitis vaccine |
|
13
|
tetanus immune globulin |
|
78
|
tularemia vaccine |
|
190
|
Typhoid conjugate vaccine (non-US) |
|
25
|
typhoid vaccine, live, oral |
|
41
|
typhoid vaccine, parenteral, other than acetone-killed, dried |
|
53
|
typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) |
|
91
|
typhoid vaccine, unspecified formulation |
|
101
|
typhoid Vi capsular polysaccharide vaccine |
|
999
|
unknown vaccine or immune globulin |
|
75
|
vaccinia (smallpox) vaccine |
|
105
|
vaccinia (smallpox) vaccine, diluted |
|
79
|
vaccinia immune globulin |
|
21
|
varicella virus vaccine |
|
81
|
Venezuelan equine encephalitis, inactivated |
|
80
|
Venezuelan equine encephalitis, live, attenuated |
|
92
|
Venezuelan equine encephalitis vaccine, unspecified formulation |
|
36
|
varicella zoster immune globulin |
|
37
|
yellow fever vaccine |
|
183
|
Yellow fever vaccine alternative formulation |
|
184
|
Yellow fever vaccine, unspecified formulation |